金斯瑞生物科技(01548.HK)联营传奇生物宣布截至2025年12月31日止季度CARVYKTI®初步销售额约5.55亿美元

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its associate company, Legend Biotech, has submitted a 6-K form to the U.S. Securities and Exchange Commission, reporting trade sales net revenue of approximately $555 million for CARVYKTI® for the quarter ending December 31, 2025 [1]. Group 1 - The announcement was made on January 21, 2026, after the Hong Kong trading session [1]. - The trade sales net revenue figure is based on information provided by Janssen Biotech, Inc., and has not been independently verified by either Legend or Kingsray [1].